Day 1 Morning Session (9:00 to 11:30 AM)

9:00-9:30 AM Welcome Remarks
Philip Castle, Ph.D., M.P.H., Director, Division of Cancer Prevention, NCI
Mark Miller, Ph.D., Program Director, Division of Cancer Prevention, NCI

Session I*
Advances in Small Molecule Agent Development
Co-Chairs: Margie Clapper, Ph.D. and Thomas Kensler, Ph.D.

9:30-10:00 AM Speaker 1: Margie Clapper, Ph.D., Fox Chase Cancer Center
Estrogen metabolism: A target for intervention in non-small cell lung cancer

10:00-10:30 AM Speaker 2: Karen Liby, Ph.D., Michigan State University
Targeting the immune system for the prevention of Kras-driven cancers

10:30-11:00 AM Speaker 3: Zelton (Dave) Sharp, Ph.D., University of Texas at San Antonio
Cancer and aging prevention by mTOR inhibition

11:00-11:30 AM Speaker 4: Thomas Kensler, Ph.D., Fred Hutchinson Cancer Research Center
Bringing broccoli sprouts (Sulforaphane) to clinical trials: dose matters

11:30-12:15 PM Break

Day 1 Early Afternoon Session (12:15 to 3:15 PM)

12:15-1:15 AM Translational Research Plenary Speaker
Raymond DuBois, M.D., Ph.D., Medical University of South Carolina
Inflammation and inflammatory mediators as targets for cancer prevention/interception

*Session talks will be 20 min with 10 min Q&A
Session II

Advances in Immunomodulatory Agent Development
Co-chairs: Jill Siegfried, Ph.D. and Robert H. Shoemaker, Ph.D.

1:15-1:45 PM Speaker 1: Jill Siegfried, Ph.D., University of Minnesota
A STAT3 decoy for lung cancer prevention

1:45-2:15 PM Speaker 2: Robert Glynn, Sc.D., Harvard Medical School
Mediation analysis to elucidate the role of inflammation reduction in cancer prevention: exploratory findings from the CANTOS trial

2:15-2:45 PM Speaker 3: Haval Shirwan, Ph.D., University of Missouri, Columbia
CD137 immune checkpoint pathway as an effective target for cancer immunoprevention

2:45-3:15 PM Speaker 4: Shadmehr Demehri, M.D., Ph.D., Massachusetts General Hospital
Epithelium-derived alarmins role in breast cancer immunoprevention

3:15 – 4:00 PM Break

Day 1 Late Afternoon Session (4:00 to 6:30 PM)

Session III

Alternative Dosing and Combination Strategies to Reduce Toxicity
Co-Chairs: Ming You, M.D., Ph.D. and Altaf Mohammed, Ph.D.

4:00-4:30 PM Speaker 1: Ming You, M.D., Ph.D., Wisconsin Medical Center
Chemoprevention with aerosolized let-7 micro-RNA in mouse models of lung cancer

4:30- 5:00 PM Speaker 2: Susan Mallery, D.D.S., Ph.D., Ohio State University
Location, location, location: oral cancer chemoprevention by local delivery

5:00-5:30 PM Speaker 3: C.V. Rao, Ph.D., University of Oklahoma
Safer chemopreventive approaches to colonic adenoma prevention

5:30-6:00 PM Speaker 4: D. Lynn Kirkpatrick, Ph.D., PHusis Therapeutics
Preventing Skin cancer in high risk individuals with Actinic Keratosis using targeted AKT/PDK1 inhibitor, PHT-427

6:00-6:30 PM Speaker 5: Roderick Dashwood, Ph.D., Texas A&M Health Science Center
Optimizing dosing regimens of Erlotinib and Sulindac in a preclinical model of FAP
**Day 2 Morning Session (10:00 AM to 1:30 PM)**

10:00-10:15 AM  **Open Morning Session**  
Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI

10:15-11:00 AM  **NCI PREVENT Preclinical Drug Development Program**  
Mark Miller, Ph.D., Division of Cancer Prevention, NCI

**Session IV**

Emerging Vaccines for Cancer Prevention  
*Co-Chairs: Steven Lipkin, M.D., Ph.D. and Shizuko Sei, M.D.*

11:00-11:30 AM  Speaker 1: Steven Lipkin, M.D., Ph.D. Weill Cornell University  
*Immunoprevention for Lynch Syndrome*

11:30-12:00 PM  Speaker 2: Robert Schoen, M.D., M.P.H., University of Pittsburgh  
*MUC1 vaccine for prevention of colorectal adenoma*

12:00-12:30 PM  Speaker 3: Richard Roden, Ph.D., Johns Hopkins University  
*Development of vaccines for broad protection against and elimination of HPV infection*

12:30-1:00 PM  Speaker 4: Bryon Johnson, Ph.D., Wisconsin Medical Center  
*Development of a Kras preventive vaccine*

1:00-1:30 PM  Speaker 5: Mary (Nora) Disis, M.D., University of Washington  
*Vaccines targeting cancer initiation associated proteins*

1:30-2:30 PM Break

**Day 2 Afternoon Session (2:30 to 6:15 PM)**

2:30-3:30 PM  **Clinical Research Plenary Speaker**  
Powel Brown, M.D., Ph.D., MD Anderson Cancer Center  
*Novel cancer prevention strategies in the molecular era*

**Session V**

Cancer Prevention Clinical Trials  
*Co-Chairs: Peter Allen, M.D. and Eva Szabo, M.D.*

3:30-4:00 PM  **Overview of the Cancer Prevention Clinical Trials Network (CP-CTNet)**  
Eva Szabo, M.D., Division of Cancer Prevention, NCI
4:00-4:30 PM  Speaker 1: Peter Allen, M.D., Duke University

*Intraductal Papillary Mucinous neoplasms of the pancreas: An opportunity to prevent pancreatic cancer?*

4:30-5:00 PM  Speaker 2, Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson Cancer Center

*Cancer immune-interception for Lynch Syndrome*

5:00-5:30 PM  Speaker 3: Seema Khan, M.D., Northwestern University

*Local transdermal drug delivery to the breast for cancer prevention*

5:30-6:00 PM  Speaker 4: Andrew Chan, M.D., M.P.H., Massachusetts General Hospital

*Novel strategies for aspirin prevention of cancer*

6:00-6:15 PM  **Closing Remarks, Future Plans for Prevention Meetings**

Altaf Mohammed, Ph.D., Division of Cancer Prevention, NCI

Mark Miller, Ph.D., Division of Cancer Prevention, NCI